BIO-TECHNE Corp Debt Securities, Available-for-sale, Amortized Cost
BIO-TECHNE Corp (TECH) had Debt Securities, Available-for-sale, Amortized Cost of $32.49 million as of 2016-06-30, per its 10-K filed 2016-08-29.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2016-08-29
- 2016-06-30: Debt Securities, Available-for-sale, Amortized Cost $32.49M.
- 2015-06-30: Debt Securities, Available-for-sale, Amortized Cost $33.56M.
- 2014-06-30: Debt Securities, Available-for-sale, Amortized Cost $40.74M.
- 2011-06-30: Debt Securities, Available-for-sale, Amortized Cost $194.17M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2016-06-30 | $32.49M 10-K · filed 2016-08-29 |
| 2015-06-30 | $33.56M 10-K · filed 2016-08-29 |
| 2014-06-30 | $40.74M 10-K · filed 2015-08-31 |
| 2011-06-30 | $194.17M 10-K · filed 2011-08-29 |
| 2010-06-30 | $214.70M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |